Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

BACKGROUND: Immunotherapy targeting PD-1/PD-L1 fails to induce clinical responses in most patients with solid cancers. N-803, formerly ALT-803, is an IL-15 superagonist mutant and dimeric IL-15RαSushi-Fc fusion protein complex that enhances CD8(+) T and NK cell expansion and function and exhibits an...

Descripción completa

Detalles Bibliográficos
Autores principales: Knudson, Karin M., Hicks, Kristin C., Alter, Sarah, Schlom, Jeffrey, Gameiro, Sofia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429734/
https://www.ncbi.nlm.nih.gov/pubmed/30898149
http://dx.doi.org/10.1186/s40425-019-0551-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429734/
https://www.ncbi.nlm.nih.gov/pubmed/30898149
http://dx.doi.org/10.1186/s40425-019-0551-y

Ejemplares similares